-
公开(公告)号：KR1020110120195A
公开(公告)日：2011-11-03
申请号：KR1020100132775
申请日：2010-12-22
Applicant: 포항공과대학교 산학협력단
CPC classification number: A61K38/18
Abstract: PURPOSE: A pharmaceutical composition related to angiogenesis using connective-tissue growth factors is provided to effectively induce FPRL1-specific ERK phosphorylation. CONSTITUTION: A composition for promoting angiogenesis contains a fragment of connective-tissue growth factor having 38 or more serial amino acids having an amino acid of sequence number 5 or a gene encoding the same as an active ingredient. The fragment of the connective-tissue growth factor is denoted by sequence number 5 or 6. A siRNA of FPRL1(formyl peptide receptor-like 1) has sequence numbers 3 and 4. A composition for promoting angiogenesis contains the siRNA as an active ingredient.
Abstract translation: 目的：提供与使用结缔组织生长因子的血管生成相关的药物组合物，以有效诱导FPRL1特异性ERK磷酸化。 构成：用于促进血管发生的组合物含有具有38个或更多个具有序列号5的氨基酸的序列氨基酸的结缔组织生长因子的片段或与其编码活性成分的基因。 结缔组织生长因子的片段由序列号5或6表示.FPRL1（甲酰基肽受体样1）的siRNA具有序列号3和4.用于促进血管生成的组合物含有siRNA作为活性成分。
-
12.发明授权포스포리파제 Ｄ 및 ＲＨＥＢ의 상호작용에 의한 포유류 라파마이신 표적 (ｍ-ＴＯＲ) 활성의 조절 방법 失效通过磷脂酶D和RHEB之间的相互作用调节乳腺癌靶向的RAPAMYCIN活性的方法
公开(公告)号：KR101072504B1
公开(公告)日：2011-10-11
申请号：KR1020097004571
申请日：2007-08-03
Applicant: 포항공과대학교 산학협력단
CPC classification number: C12Q1/485 , A61K38/00 , C12N9/16 , C12Q1/34 , G01N2333/9121 , G01N2333/916
Abstract: 본발명은포스포리파아제 D (PLD) 및 Rheb (Ras homolog enriched in brain)에의한 mTOR 조절메커니즘의신규한연구결과에기초한포유류라파마이신표적 (mTOR) 조절방법에관한것이다. 또한, 본발명은 mTOR 억제제검출방법, mTOR 억제제에의한 mTOR 관련대사성질환의치료용조성물및 치료방법에관한것이다.
-
公开(公告)号：KR101020933B1
公开(公告)日：2011-03-09
申请号：KR1020100015396
申请日：2010-02-19
Applicant: 포항공과대학교 산학협력단
Abstract: PURPOSE: A method for searching for a non-antibody protein that is specific to a target through simulation from an electronic library is provided to remarkably improve speed and to save costs. CONSTITUTION: A method for searching for a non-antibody protein that is specific to a target from an electronic library comprises: a step of performing a docking simulation using a non-antibody protein and target to select a non-antibody protein that is bound in more than a number of predetermined target residues; a step of calculating the binding energy of the non-antibody protein and target and arranging a non-antibody protein according the predetermined number; and a step of removing a non-antibody protein which has a level less than the predetermined level. The electronic library comprises a non-antibody protein forming a monomer, homodimer, or homotrimer.
Abstract translation: 目的：提供一种通过电子图书馆模拟搜索特异于靶标的非抗体蛋白质的方法，显着提高速度并节约成本。 构成：从电子文库搜索靶标特异性的非抗体蛋白质的方法包括：使用非抗体蛋白质和靶标进行对接模拟的步骤，以选择结合于非抗体蛋白质的非抗体蛋白质 超过一定数量的预定目标残留物; 计算非抗体蛋白质和靶标的结合能量并按照预定数量排列非抗体蛋白质的步骤; 以及去除具有低于预定水平的水平的非抗体蛋白质的步骤。 电子文库包含形成单体，同二聚体或同三聚物的非抗体蛋白质。
-
14.发明公开포스포리파제 Ｄ 및 ＲＨＥＢ의 상호작용에 의한 포유류 라파마이신 표적 (ｍ-ＴＯＲ) 활성의 조절 방법 失效通过磷脂酶D和RHEB之间的相互作用调节乳腺癌靶向的RAPAMYCIN活性的方法
公开(公告)号：KR1020090040364A
公开(公告)日：2009-04-23
申请号：KR1020097004571
申请日：2007-08-03
Applicant: 포항공과대학교 산학협력단
CPC classification number: C12Q1/485 , A61K38/00 , C12N9/16 , C12Q1/34 , G01N2333/9121 , G01N2333/916
Abstract: A method of regulating mammalian target-of-rapamycin(mTOR) activity based on mTOR control mechanism by phospholipase D(PLD) AND Rheb(Ras homolog enriched in brain) is provided to cure mTOR-related metabolic disease through the mTOR suppression. A method of regulating mammalian target-of-rapamycin(mTOR) activity comprises (i) coupling Rheb and mTOR through PLD2 by interaction between phospholipase D 2(PLD2) and Rheb; (ii) increasing the concentration of PA by moving phosphatidic acid(PA) produced from PLD2 to adjacent mTOR; and (iii) increasing mTOR kinase activity by coupling Rheb with mTOR through the increase of PA density around the adjacent mTOR.
Abstract translation: 提供基于mTOR通过磷脂酶D（PLD）的控制机制调节哺乳动物雷帕霉素（mTOR）活性的方法和Rheb（Ras同源物富含脑），以通过mTOR抑制来治愈mTOR相关代谢疾病。 调节哺乳动物雷帕霉素靶向（mTOR）活性的方法包括：（i）通过磷脂酶D 2（PLD2）和Rheb之间的相互作用使PLD2连接Rheb和mTOR; （ii）通过将由PLD2产生的磷脂酸（PA）移动到相邻的mTOR来增加PA的浓度; 和（iii）通过在相邻mTOR周围增加PA密度增加，通过将Rheb与mTOR偶联来增加mTOR激酶活性。
-
公开(公告)号：KR1020090037498A
公开(公告)日：2009-04-15
申请号：KR1020097004570
申请日：2007-08-03
Applicant: 포항공과대학교 산학협력단
CPC classification number: A61K38/1709 , C07K14/4702 , C12N9/20 , C12Y301/04004 , G01N33/5011 , G01N2333/9121 , G01N2333/916
Abstract: A method for controlling the activity of mTOR(mammalian target-of-rapamycin) with the interaction of phospholipase D(PLD) and raptor is provided to cure metabolic diseases related with mTOR by controlling mTOR through the control of the PLD activity. A method for controlling the activity of mTOR(mammalian target-of-rapamycin) is to suppress PLD2 through raptor and mTOR complex(PLD/raptor/mTOR complex) by suppressing the interaction of PLD2 and raptor. Suppressing the formation of the PLD/raptor/mTOR complex is performed by inactivating a raptor binding domain of PLD2 or a PLD2 binding domain of raptor.
Abstract translation: 提供了通过控制mTOR通过控制PLD活性来控制mTOR（哺乳动物雷帕霉素靶）与磷脂酶D（PLD）和猛禽相互作用的活性的方法，以治疗与mTOR相关的代谢疾病。 用于控制mTOR（哺乳动物雷帕霉素靶）活性的方法是通过抑制PLD2和猛禽的相互作用来抑制PLD2通过猛禽和mTOR复合物（PLD / raptor / mTOR复合物）。 抑制PLD / raptor / mTOR复合物的形成是通过灭活猛禽的PLD2或PLD2结合结构域的猛禽结合结构域来实现的。
-
Patent Agency Ranking
公开(公告)号：KR1020080012636A
公开(公告)日：2008-02-12
申请号：KR1020060073778
申请日：2006-08-04
Applicant: 포항공과대학교 산학협력단 , 학교법인 포항공과대학교
IPC: C07K2/00
Abstract: A peptide for activating a mast cell is provided to control calcium increase or degranulation of the mast cell by regulating the activity of the mast cell, so that the peptide is useful for immunotreatment of various diseases associated with the mast cell. An immunomodulator for treating diseases associated with the mast cell such as allergy disease comprises a peptide capable of activating a mast cell by increasing calcium or inducing degranulation of the mast cell, having the amino acid sequence of SEQ ID NO:1 or a peptide having 70% or more homology thereto, wherein the daily dosage of the immunomodulator is 0.4-4 mg/kg.
Abstract translation: 提供了用于激活肥大细胞的肽，以通过调节肥大细胞的活性来控制肥大细胞的钙增加或脱颗粒，使得该肽可用于与肥大细胞相关的各种疾病的免疫治疗。 用于治疗与肥大细胞相关的疾病如过敏疾病的免疫调节剂包括能够通过增加钙或诱导具有SEQ ID NO：1的氨基酸序列的肥大细胞的脱颗粒或具有70的肽的活化肥大细胞的肽 ％以上的同源性，其中免疫调节剂的日剂量为0.4-4mg / kg。
-
公开(公告)号：KR1020070108836A
公开(公告)日：2007-11-13
申请号：KR1020070106121
申请日：2007-10-22
Applicant: 주식회사 포스코 , 포항공과대학교 산학협력단
CPC classification number: C07K7/06 , A61K38/00 , C07K5/081 , C07K5/1016 , C07K5/1019 , C12N2799/021
Abstract: An immune-modulating peptide is provided to reduce or inhibit side effects of drug and drug candidate materials by activating formyl peptide receptor(FPR) and formyl peptide receptor-like 1(FPRL1) expressed from phagocytic cells, thereby activating various molecules and inducing downstream signaling. An immune-modulating peptide comprises one selected from the amino acid sequences of SEQ ID NO:1 to SEQ ID NO:24, and has at least one properties selected from (a) induction of superoxide production in human monocyte or neutrophil, (b) binding with formyl peptide receptor(FPR) and formyl peptide receptor-like 1(FPRL1), (c) induction of in vitro chemotactic migration of human monocyte or neutrophil, (d) induction of degranulation in formyl peptide receptor-like 1(FPRL1) expression cells, (e) increase of extracellular signal-controlled protein kinase phosphorylation through binding with formyl peptide receptor(FPR) and formyl peptide receptor-like 1(FPRL1), and (f) increase protein kinase B(Akt) phosphorylation through binding with formyl peptide receptor(FPR) and formyl peptide receptor-like 1(FPRL1).
Abstract translation: 通过激活吞噬细胞表达的甲酰肽受体（FPR）和甲酰肽受体样1（FPRL1），从而激活各种分子并诱导下游信号传导，提供免疫调节肽以减少或抑制药物和药物候选物质的副作用 。 免疫调节肽包含选自SEQ ID NO：1至SEQ ID NO：24的氨基酸序列的一种，并且具有选自（a）在人单核细胞或嗜中性粒细胞中诱导超氧化物产生的至少一种性质，（b） 结合甲酰肽受体（FPR）和甲酰肽受体样1（FPRL1），（c）诱导人单核细胞或嗜中性粒细胞的体外趋化迁移，（d）诱导甲酰肽受体样1（FPRL1）中的脱颗粒 表达细胞，（e）通过与甲酰基肽受体（FPR）和甲酰肽受体样1（FPRL1）结合增加细胞外信号控制的蛋白激酶磷酸化，和（f）通过与...结合而增加蛋白激酶B（Akt）磷酸化 甲酰肽受体（FPR）和甲酰肽受体样1（FPRL1）。
-
公开(公告)号：KR101501221B1
公开(公告)日：2015-03-16
申请号：KR1020130038148
申请日：2013-04-08
Applicant: 포항공과대학교 산학협력단
IPC: A61K31/337 , A61K31/165 , A61P35/00 , A61P3/10
Abstract: 본 발명은 Rheb(Ras homolog enriched in the brain) 및 튜불린(tubulin)의 상호작용에 의한 Rheb에 결합하는 뉴클레오티드의 조절 및 상기 조절을 통한 mTOR 활성과의 관계를 밝혀낸 연구 결과에 기초한 것으로, 구체적으로는 튜불린(tubulin)의 중합 또는 아세틸화 조절제를 유효성분으로 포함하여 Rheb(Ras homolog enriched in the brain)-GTP 복합체의 세포내 수준을 조절하는 것인 mTOR 활성 조절제 및 상기 활성 조절제의 검출 방법에 관한 것이다.
-
公开(公告)号：KR1020090048160A
公开(公告)日：2009-05-13
申请号：KR1020070114408
申请日：2007-11-09
Applicant: 포항공과대학교 산학협력단
Abstract: 본 발명은 에스트로겐 또는 이의 유사물질, 및 다이옥신 또는 이의 유사물질을 동시에 검출하는 형질전환 세포주를 이용한 바이오센서 및 그의 효능에 관한 것으로, 보다 상세하게는 1개 이상의 에스트로겐 반응 인자, 이와 작동 가능하게 연결된 하나의 프로모터 및 제1의 리포터 유전자를 포함하는 재조합 벡터; 및 1개 이상의 다이옥신 반응 인자, 이와 작동 가능하게 연결된 하나의 프로모터 및 제2의 리포터 유전자를 포함하는 재조합 벡터를 모두 포함하는 형질전환 세포주를 이용하여 에스트로겐 또는 이의 유사물질, 및 다이옥신 또는 이의 유사물질을 동시에 그리고 신속하게 검출할 수 있는 바이오센서 및 그의 효능에 관한 것이다.
에스트로겐, 다이옥신, 바이오센서-
公开(公告)号：KR100845278B1
公开(公告)日：2008-07-09
申请号：KR1020060073778
申请日：2006-08-04
Applicant: 포항공과대학교 산학협력단 , 학교법인 포항공과대학교
IPC: C07K2/00
Abstract: 본 발명은 비만 세포의 활성을 유도하는 펩타이드 및 이를 포함하는 면역 조절제에 관한 것으로, 상기 펩타이드는 서열번호: 1의 아미노산 서열을 가지거나 상기 서열번호: 1의 아미노산 서열과 70% 이상의 상동성을 가진다. 본 발명의 면역 조절제는 비만 세포가 관여하는 각종 알러지성 질환의 면역치료에 효과적으로 사용될 수 있다.
비만세포, 펩타이드, 탈과립, 칼슘, 알러지성 질환
-
-
-
-
-
-
-
-
-
Search Results
36
records
(took 0.052 seconds)
